Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 17/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.43 |
| ▸ | CCND1 | P24385 | 7/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 7/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.43 |
| ▸ | CDK7 | P50613 | 7/20 | 0.43 |
| ▸ | CCNH | P51946 | 7/20 | 0.43 |
| ▸ | MNAT1 | P51948 | 7/20 | 0.43 |
| ▸ | CCNK | O75909 | 4/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3674729 | 1.00 | MAPK14 (0.48) | MAPK14CDK2CCNE1CCND1CDK6 | |
| SCHEMBL3669704 | 0.96 | MAPK14 (0.50) | MAPK14CDK2CCNE1CCND1CDK6 | |
| SCHEMBL4765796 | 0.94 | CDK2 (0.45) | MAPK14CDK2CCNE1CCND1CDK6 | |
| SCHEMBL3677074 | 0.94 | CDK2 (0.45) | MAPK14CDK2CCNE1CCND1CDK6 | |
| SCHEMBL3674104 | 0.94 | CDK2 (0.45) | MAPK14CDK2CCNE1CCND1CDK6 | |
| SCHEMBL4722727 | 0.91 | CCNE1 (0.49) | MAPK14CDK2CCNE1CCND1CDK6 | |
| SCHEMBL3673605 | 0.91 | CCNE1 (0.49) | MAPK14CDK2CCNE1CCND1CDK6 | |
| SCHEMBL3669287 | 0.91 | CCNE1 (0.49) | MAPK14CDK2CCNE1CCND1CDK6 | |
| SCHEMBL3670797 | 0.90 | CDK2 (0.47) | MAPK14CDK2CCNE1CCND1CDK6 | |
| SCHEMBL3673722 | 0.90 | MAPK14 (0.47) | MAPK14CDK2CCNE1CCND1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| EP-2111861-A1 | Compositions of phosphodiesterase type IV inhibitors | Ranbaxy Laboratories Limited (IN) | 2009-10-28 | — | — | EP | disclosed |
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | PNPO, TPMT, NOD1 | MAPK14 1920/4885CDK2 393/4885CCNE1 863/4885 |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | MAPK14 136/4885CDK2 944/4885CCNE1 4327/4885 |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | MAPK14 136/4885CDK2 936/4885CCNE1 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.